Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma

“Inflammatory rhabdomyoblastic tumor” (IRMT) is a recently coined name for a distinctive soft tissue neoplasm characterized by slow growth, a dense histiocytic infiltrate, scattered, bizarre-appearing tumor cells with morphologic and immunohistochemical evidence of skeletal muscle differentiation, a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern pathology 2023-06, Vol.36 (6), p.100131-100131, Article 100131
Hauptverfasser: Dehner, Carina A., Geiersbach, Katherine, Rowsey, Ross, Murugan, Paari, Broski, Stephen M., Meis, Jeanne M., Rosenberg, Andrew E., Folpe, Andrew L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 100131
container_issue 6
container_start_page 100131
container_title Modern pathology
container_volume 36
creator Dehner, Carina A.
Geiersbach, Katherine
Rowsey, Ross
Murugan, Paari
Broski, Stephen M.
Meis, Jeanne M.
Rosenberg, Andrew E.
Folpe, Andrew L.
description “Inflammatory rhabdomyoblastic tumor” (IRMT) is a recently coined name for a distinctive soft tissue neoplasm characterized by slow growth, a dense histiocytic infiltrate, scattered, bizarre-appearing tumor cells with morphologic and immunohistochemical evidence of skeletal muscle differentiation, a near-haploid karyotype with retained biparental disomy of chromosomes 5 and 22, and usually indolent behavior. There are 2 reports of rhabdomyosarcoma (RMS) arising in IRMT. We studied the clinicopathologic and cytogenomic features of 6 cases of IRMT with progression to RMS. Tumors occurred in the extremities of 5 men and 1 woman (median patient age, 50 years; median tumor size, 6.5 cm). Clinical follow-up (6 patients: median, 11 months; range 4-163 months) documented local recurrence and distant metastases in 1 and 5 of 6 patients, respectively. Therapy included complete surgical resection (4 patients) and adjuvant/neoadjuvant chemo/radiotherapy (6 patients). One patient died of disease, 4 were alive with metastatic disease, and one was without evidence of disease. All primary tumors contained conventional IRMT. Progression to RMS appeared as follows: (1) overgrowth of monomorphic rhabdomyoblasts with diminished histiocytes, (2) monomorphic spindle cell morphology with variably pleomorphic rhabdomyoblasts and low mitotic activity, or (3) morphologically undifferentiated spindle cell and epithelioid sarcoma. All but one were diffusely desmin-positive, with more limited MyoD1/myogenin expression. All RMS arising in IRMT, either primary or metastatic, demonstrated widespread loss of heterozygosity with retained heterozygosity of chromosomes 5 and 20, and all but one displayed additional gains and losses involving loci containing oncogenes/ tumor suppressor genes, most often CDKN2A and CDKN2B. RMS arising in IRMT have unique clinicopathologic and cytogenomic features, warranting classification as a distinct, potentially aggressive RMS subtype. It should be distinguished from other RMSs, particularly fusion-driven spindle cell RMS and pleomorphic RMS.
doi_str_mv 10.1016/j.modpat.2023.100131
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2791704042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0893395223000364</els_id><sourcerecordid>2791704042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-cf0d994c8188fc6f69ef1f03c77291fea10c2b658bda449421a628157f82c0f33</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi1EBVvoP0DIRy7Z-iNxbA5IK6AUCalSoWfLccbgVRwvdrJS_n2DQjlw6GmkmWfm1TwInVGypoSK79t1iO3ODGtGGJ9bhHJ6gFa04qQgTFaHaEWk4gVXFTtGX3PezkhZSXaEjrlQQlQVW6H97xfTtDFMMZtkYzB4k3z2_TP2Pb7vXWdCMENME_4Am87kwVv8NIaYLvEG30EPc8N03YRv_Dzr7eD3gB_HZph2gKPDn1NO0Rdnugzf3usJ-vPj9un6Z_Hw6-7-evNQWC7YUFhHWqVKK6mUzgonFDjqCLd1zRR1YCixrBGVbFpTlqpk1AgmaVU7ySxxnJ-gi-XuLsXXEfKgg88Wus70EMesWa1oTUpSshktF9SmmHMCp3fJB5MmTYl-M663ejGu34zrxfi8dv6eMDYB2o-lf4pn4GoBYP5z7yHpbD30FlqfwA66jf7_CX8B1w-VyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791704042</pqid></control><display><type>article</type><title>Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma</title><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Dehner, Carina A. ; Geiersbach, Katherine ; Rowsey, Ross ; Murugan, Paari ; Broski, Stephen M. ; Meis, Jeanne M. ; Rosenberg, Andrew E. ; Folpe, Andrew L.</creator><creatorcontrib>Dehner, Carina A. ; Geiersbach, Katherine ; Rowsey, Ross ; Murugan, Paari ; Broski, Stephen M. ; Meis, Jeanne M. ; Rosenberg, Andrew E. ; Folpe, Andrew L.</creatorcontrib><description>“Inflammatory rhabdomyoblastic tumor” (IRMT) is a recently coined name for a distinctive soft tissue neoplasm characterized by slow growth, a dense histiocytic infiltrate, scattered, bizarre-appearing tumor cells with morphologic and immunohistochemical evidence of skeletal muscle differentiation, a near-haploid karyotype with retained biparental disomy of chromosomes 5 and 22, and usually indolent behavior. There are 2 reports of rhabdomyosarcoma (RMS) arising in IRMT. We studied the clinicopathologic and cytogenomic features of 6 cases of IRMT with progression to RMS. Tumors occurred in the extremities of 5 men and 1 woman (median patient age, 50 years; median tumor size, 6.5 cm). Clinical follow-up (6 patients: median, 11 months; range 4-163 months) documented local recurrence and distant metastases in 1 and 5 of 6 patients, respectively. Therapy included complete surgical resection (4 patients) and adjuvant/neoadjuvant chemo/radiotherapy (6 patients). One patient died of disease, 4 were alive with metastatic disease, and one was without evidence of disease. All primary tumors contained conventional IRMT. Progression to RMS appeared as follows: (1) overgrowth of monomorphic rhabdomyoblasts with diminished histiocytes, (2) monomorphic spindle cell morphology with variably pleomorphic rhabdomyoblasts and low mitotic activity, or (3) morphologically undifferentiated spindle cell and epithelioid sarcoma. All but one were diffusely desmin-positive, with more limited MyoD1/myogenin expression. All RMS arising in IRMT, either primary or metastatic, demonstrated widespread loss of heterozygosity with retained heterozygosity of chromosomes 5 and 20, and all but one displayed additional gains and losses involving loci containing oncogenes/ tumor suppressor genes, most often CDKN2A and CDKN2B. RMS arising in IRMT have unique clinicopathologic and cytogenomic features, warranting classification as a distinct, potentially aggressive RMS subtype. It should be distinguished from other RMSs, particularly fusion-driven spindle cell RMS and pleomorphic RMS.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1016/j.modpat.2023.100131</identifier><identifier>PMID: 36966552</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cytogenomics ; Haploidy ; Inflammatory leiomyosarcoma ; Inflammatory rhabdomyoblastic tumor ; Rhabdomyosarcoma ; Single-nucleotide polymorphism</subject><ispartof>Modern pathology, 2023-06, Vol.36 (6), p.100131-100131, Article 100131</ispartof><rights>2023 United States &amp; Canadian Academy of Pathology</rights><rights>Copyright © 2023 United States &amp; Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-cf0d994c8188fc6f69ef1f03c77291fea10c2b658bda449421a628157f82c0f33</citedby><cites>FETCH-LOGICAL-c362t-cf0d994c8188fc6f69ef1f03c77291fea10c2b658bda449421a628157f82c0f33</cites><orcidid>0000-0002-0273-7351</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,64387</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36966552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dehner, Carina A.</creatorcontrib><creatorcontrib>Geiersbach, Katherine</creatorcontrib><creatorcontrib>Rowsey, Ross</creatorcontrib><creatorcontrib>Murugan, Paari</creatorcontrib><creatorcontrib>Broski, Stephen M.</creatorcontrib><creatorcontrib>Meis, Jeanne M.</creatorcontrib><creatorcontrib>Rosenberg, Andrew E.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><title>Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><description>“Inflammatory rhabdomyoblastic tumor” (IRMT) is a recently coined name for a distinctive soft tissue neoplasm characterized by slow growth, a dense histiocytic infiltrate, scattered, bizarre-appearing tumor cells with morphologic and immunohistochemical evidence of skeletal muscle differentiation, a near-haploid karyotype with retained biparental disomy of chromosomes 5 and 22, and usually indolent behavior. There are 2 reports of rhabdomyosarcoma (RMS) arising in IRMT. We studied the clinicopathologic and cytogenomic features of 6 cases of IRMT with progression to RMS. Tumors occurred in the extremities of 5 men and 1 woman (median patient age, 50 years; median tumor size, 6.5 cm). Clinical follow-up (6 patients: median, 11 months; range 4-163 months) documented local recurrence and distant metastases in 1 and 5 of 6 patients, respectively. Therapy included complete surgical resection (4 patients) and adjuvant/neoadjuvant chemo/radiotherapy (6 patients). One patient died of disease, 4 were alive with metastatic disease, and one was without evidence of disease. All primary tumors contained conventional IRMT. Progression to RMS appeared as follows: (1) overgrowth of monomorphic rhabdomyoblasts with diminished histiocytes, (2) monomorphic spindle cell morphology with variably pleomorphic rhabdomyoblasts and low mitotic activity, or (3) morphologically undifferentiated spindle cell and epithelioid sarcoma. All but one were diffusely desmin-positive, with more limited MyoD1/myogenin expression. All RMS arising in IRMT, either primary or metastatic, demonstrated widespread loss of heterozygosity with retained heterozygosity of chromosomes 5 and 20, and all but one displayed additional gains and losses involving loci containing oncogenes/ tumor suppressor genes, most often CDKN2A and CDKN2B. RMS arising in IRMT have unique clinicopathologic and cytogenomic features, warranting classification as a distinct, potentially aggressive RMS subtype. It should be distinguished from other RMSs, particularly fusion-driven spindle cell RMS and pleomorphic RMS.</description><subject>Cytogenomics</subject><subject>Haploidy</subject><subject>Inflammatory leiomyosarcoma</subject><subject>Inflammatory rhabdomyoblastic tumor</subject><subject>Rhabdomyosarcoma</subject><subject>Single-nucleotide polymorphism</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1P3DAQhi1EBVvoP0DIRy7Z-iNxbA5IK6AUCalSoWfLccbgVRwvdrJS_n2DQjlw6GmkmWfm1TwInVGypoSK79t1iO3ODGtGGJ9bhHJ6gFa04qQgTFaHaEWk4gVXFTtGX3PezkhZSXaEjrlQQlQVW6H97xfTtDFMMZtkYzB4k3z2_TP2Pb7vXWdCMENME_4Am87kwVv8NIaYLvEG30EPc8N03YRv_Dzr7eD3gB_HZph2gKPDn1NO0Rdnugzf3usJ-vPj9un6Z_Hw6-7-evNQWC7YUFhHWqVKK6mUzgonFDjqCLd1zRR1YCixrBGVbFpTlqpk1AgmaVU7ySxxnJ-gi-XuLsXXEfKgg88Wus70EMesWa1oTUpSshktF9SmmHMCp3fJB5MmTYl-M663ejGu34zrxfi8dv6eMDYB2o-lf4pn4GoBYP5z7yHpbD30FlqfwA66jf7_CX8B1w-VyQ</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Dehner, Carina A.</creator><creator>Geiersbach, Katherine</creator><creator>Rowsey, Ross</creator><creator>Murugan, Paari</creator><creator>Broski, Stephen M.</creator><creator>Meis, Jeanne M.</creator><creator>Rosenberg, Andrew E.</creator><creator>Folpe, Andrew L.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0273-7351</orcidid></search><sort><creationdate>20230601</creationdate><title>Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma</title><author>Dehner, Carina A. ; Geiersbach, Katherine ; Rowsey, Ross ; Murugan, Paari ; Broski, Stephen M. ; Meis, Jeanne M. ; Rosenberg, Andrew E. ; Folpe, Andrew L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-cf0d994c8188fc6f69ef1f03c77291fea10c2b658bda449421a628157f82c0f33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cytogenomics</topic><topic>Haploidy</topic><topic>Inflammatory leiomyosarcoma</topic><topic>Inflammatory rhabdomyoblastic tumor</topic><topic>Rhabdomyosarcoma</topic><topic>Single-nucleotide polymorphism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dehner, Carina A.</creatorcontrib><creatorcontrib>Geiersbach, Katherine</creatorcontrib><creatorcontrib>Rowsey, Ross</creatorcontrib><creatorcontrib>Murugan, Paari</creatorcontrib><creatorcontrib>Broski, Stephen M.</creatorcontrib><creatorcontrib>Meis, Jeanne M.</creatorcontrib><creatorcontrib>Rosenberg, Andrew E.</creatorcontrib><creatorcontrib>Folpe, Andrew L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dehner, Carina A.</au><au>Geiersbach, Katherine</au><au>Rowsey, Ross</au><au>Murugan, Paari</au><au>Broski, Stephen M.</au><au>Meis, Jeanne M.</au><au>Rosenberg, Andrew E.</au><au>Folpe, Andrew L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma</atitle><jtitle>Modern pathology</jtitle><addtitle>Mod Pathol</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>36</volume><issue>6</issue><spage>100131</spage><epage>100131</epage><pages>100131-100131</pages><artnum>100131</artnum><issn>0893-3952</issn><eissn>1530-0285</eissn><abstract>“Inflammatory rhabdomyoblastic tumor” (IRMT) is a recently coined name for a distinctive soft tissue neoplasm characterized by slow growth, a dense histiocytic infiltrate, scattered, bizarre-appearing tumor cells with morphologic and immunohistochemical evidence of skeletal muscle differentiation, a near-haploid karyotype with retained biparental disomy of chromosomes 5 and 22, and usually indolent behavior. There are 2 reports of rhabdomyosarcoma (RMS) arising in IRMT. We studied the clinicopathologic and cytogenomic features of 6 cases of IRMT with progression to RMS. Tumors occurred in the extremities of 5 men and 1 woman (median patient age, 50 years; median tumor size, 6.5 cm). Clinical follow-up (6 patients: median, 11 months; range 4-163 months) documented local recurrence and distant metastases in 1 and 5 of 6 patients, respectively. Therapy included complete surgical resection (4 patients) and adjuvant/neoadjuvant chemo/radiotherapy (6 patients). One patient died of disease, 4 were alive with metastatic disease, and one was without evidence of disease. All primary tumors contained conventional IRMT. Progression to RMS appeared as follows: (1) overgrowth of monomorphic rhabdomyoblasts with diminished histiocytes, (2) monomorphic spindle cell morphology with variably pleomorphic rhabdomyoblasts and low mitotic activity, or (3) morphologically undifferentiated spindle cell and epithelioid sarcoma. All but one were diffusely desmin-positive, with more limited MyoD1/myogenin expression. All RMS arising in IRMT, either primary or metastatic, demonstrated widespread loss of heterozygosity with retained heterozygosity of chromosomes 5 and 20, and all but one displayed additional gains and losses involving loci containing oncogenes/ tumor suppressor genes, most often CDKN2A and CDKN2B. RMS arising in IRMT have unique clinicopathologic and cytogenomic features, warranting classification as a distinct, potentially aggressive RMS subtype. It should be distinguished from other RMSs, particularly fusion-driven spindle cell RMS and pleomorphic RMS.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36966552</pmid><doi>10.1016/j.modpat.2023.100131</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0273-7351</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0893-3952
ispartof Modern pathology, 2023-06, Vol.36 (6), p.100131-100131, Article 100131
issn 0893-3952
1530-0285
language eng
recordid cdi_proquest_miscellaneous_2791704042
source EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection
subjects Cytogenomics
Haploidy
Inflammatory leiomyosarcoma
Inflammatory rhabdomyoblastic tumor
Rhabdomyosarcoma
Single-nucleotide polymorphism
title Rhabdomyosarcoma Arising in Inflammatory Rhabdomyoblastic Tumor: A Genetically Distinctive Subtype of Rhabdomyosarcoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A28%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rhabdomyosarcoma%20Arising%20in%20Inflammatory%20Rhabdomyoblastic%20Tumor:%20A%20Genetically%20Distinctive%20Subtype%20of%20Rhabdomyosarcoma&rft.jtitle=Modern%20pathology&rft.au=Dehner,%20Carina%20A.&rft.date=2023-06-01&rft.volume=36&rft.issue=6&rft.spage=100131&rft.epage=100131&rft.pages=100131-100131&rft.artnum=100131&rft.issn=0893-3952&rft.eissn=1530-0285&rft_id=info:doi/10.1016/j.modpat.2023.100131&rft_dat=%3Cproquest_cross%3E2791704042%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2791704042&rft_id=info:pmid/36966552&rft_els_id=S0893395223000364&rfr_iscdi=true